Clinical Trial Search

Primary: Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV) — 11.0 percent change in SUV

Primary: Median Progression Free Survival (PFS) — 7.2 months

Primary: Clinical Benefit Rate (CR + PR + SD > 6 Months). — 7.1; 6.3 Percent of Participants

Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…

Primary: Progression-free Survival (PFS) - Phase II Part — 7.3; 5.6 Months — p=0.9057

Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants

Primary: Clinical Benefit Rate (CR Plus PR Plus SD) — 0; 0; 3; 1 participants

Primary: Response Rate (RR) — 4.8; 0 percentage of participants

Primary: Number of Participants With Grade 4 Toxicity

Primary: Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects — 16; 15 participants

Primary: Number of Participants With Objective Response — 0; 1; 1; 1 participants

Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants

Primary: Correlation Coefficient Between FFNP Uptake and Allred Score — 0.3215 correlation coefficient (rho) — p=0.1347

Primary: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer — 39…

Primary: Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7 — 0.028; -0.011…

Primary: 2-Year Treatment Discontinuation Rate — 31 percentage of participants — p=0.0011

Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants

Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Center for Epidemiologic Studies-Depression (CES-D) Scale Mean Total Score — 12.96; 18.02; 11.53; 9.43 Units on a scale

Primary: Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes — 41.2; 45.8 percentage of participants

Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants

Primary: Progression Free Survival Rate at 12 Weeks — 46 percentage of participants

Primary: Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score) — 53.6; 42.7 units on a scale — p=0.87

Primary: Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and…

Primary: Percentage of Patients Alive and Free of Progression at 12 Weeks (PFS12) — 52.6; 57.9 percentage of patients

Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months

Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants

Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…

Primary: Number of Participants With Overall Response — 5; 2 Participants

Primary: Number of Participants With Progression Free Survival (PFS) at 12 Months — 8; 16 Participants